GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chenguang Biotech Group Co 300138.SZ · CNY

Consumer Staples · Shenzhen · 🇨🇳 China

Compare

12.75

-2.37%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.56bn

FY2016FY2025

Net income

CN¥363.6m

FY2016FY2025

Free cash flow

CN¥77.7m

FY2016FY2025

Shareholders' equity

CN¥3.39bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥6.56bnCN¥6.99bnCN¥6.87bnCN¥6.30bnCN¥4.87bnCN¥3.91bnCN¥3.27bnCN¥3.06bnCN¥2.77bnCN¥2.14bn
Gross profitCN¥438.9mCN¥459.4mCN¥799.4mCN¥843.9mCN¥698.5mCN¥631.4mCN¥573.0mCN¥430.7mCN¥346.7mCN¥292.7m
Research and developmentCN¥166.2mCN¥128.6mCN¥97.4mCN¥129.0mCN¥94.8mCN¥82.6mCN¥49.2mCN¥29.3mCN¥125.5mCN¥82.7m
Operating incomeCN¥438.9mCN¥106.0mCN¥548.3mCN¥487.0mCN¥384.9mCN¥311.1mCN¥203.1mCN¥141.2mCN¥131.2mCN¥96.5m
Net incomeCN¥363.6mCN¥94.0mCN¥479.7mCN¥434.0mCN¥351.5mCN¥267.7mCN¥193.6mCN¥145.3mCN¥142.8mCN¥92.5m
Diluted earnings per share0.800.190.900.820.670.480.370.280.280.18

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥9.50bnCN¥9.02bnCN¥8.54bnCN¥6.92bnCN¥5.96bnCN¥4.65bnCN¥4.51bnCN¥3.36bnCN¥2.87bnCN¥2.49bn
Cash and short-term investments—CN¥1.81bnCN¥2.29bnCN¥1.16bnCN¥733.2mCN¥309.8mCN¥547.8mCN¥192.9mCN¥127.3mCN¥266.8m
Total liabilitiesCN¥6.07bnCN¥5.87bnCN¥5.01bnCN¥3.71bnCN¥3.17bnCN¥2.59bnCN¥2.77bnCN¥1.62bnCN¥1.25bnCN¥967.5m
DebtCN¥50.0mCN¥3.38bnCN¥3.47bnCN¥2.84bnCN¥2.45bnCN¥2.08bnCN¥2.20bnCN¥1.29bnCN¥900.3mCN¥651.8m
Shareholders' equityCN¥3.39bnCN¥3.11bnCN¥3.47bnCN¥3.16bnCN¥2.79bnCN¥2.06bnCN¥1.75bnCN¥1.74bnCN¥1.62bnCN¥1.50bn
Shares outstanding457m504m535m527m525m561m527m510m507m508m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥212.9m−CN¥222.8m−CN¥510.9mCN¥734.8mCN¥63.9mCN¥529.4m−CN¥24.3m−CN¥56.2m−CN¥145.9m−CN¥321.6m
Capital spending−CN¥135.3m−CN¥149.5m−CN¥189.2m−CN¥176.0m−CN¥280.8m−CN¥436.9m−CN¥265.7m−CN¥139.5m−CN¥127.8m−CN¥94.8m
Free cash flowCN¥77.7m−CN¥372.4m−CN¥700.1mCN¥558.8m−CN¥216.9mCN¥92.5m−CN¥290.1m−CN¥195.7m−CN¥273.7m−CN¥416.4m
Dividends paid−CN¥159.9m−CN¥174.1m−CN¥157.6m−CN¥69.3m−CN¥53.3m−CN¥24.1m−CN¥40.9m−CN¥78.0m−CN¥42.1m−CN¥26.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.53bnCN¥1.63bnCN¥1.52bnCN¥1.39bnCN¥1.94bnCN¥1.72bnCN¥1.77bnCN¥1.73bn
Gross profitCN¥202.4mCN¥222.9m−CN¥292.0mCN¥238.0mCN¥249.9mCN¥243.0mCN¥74.0mCN¥99.8m
Operating incomeCN¥124.5mCN¥141.6mCN¥70.2mCN¥104.7mCN¥134.2mCN¥129.8mCN¥45.8m−CN¥47.6m
Net incomeCN¥81.8mCN¥96.7mCN¥59.8mCN¥88.9mCN¥105.5mCN¥109.5mCN¥31.4m−CN¥37.2m
Diluted earnings per share0.180.210.130.190.230.240.06-0.07
Cash from operations———CN¥524.0mCN¥1.30bnCN¥530.0m—CN¥567.0m
Capital spending−CN¥34.0m−CN¥25.0m−CN¥41.0m−CN¥37.0m−CN¥30.0m−CN¥25.0m—−CN¥66.0m
Free cash flow———CN¥487.0mCN¥1.27bnCN¥505.0m—CN¥501.0m
Total assetsCN¥9.62bnCN¥11.09bnCN¥9.50bnCN¥7.96bnCN¥9.30bnCN¥10.30bnCN¥9.02bnCN¥7.75bn
Cash and short-term investments———CN¥2.14bnCN¥3.63bnCN¥3.28bnCN¥1.81bnCN¥2.55bn
DebtCN¥45.0mCN¥45.0mCN¥50.0mCN¥3.64bnCN¥3.26bnCN¥4.75bnCN¥3.37bnCN¥3.49bn
Shareholders' equityCN¥3.40bnCN¥3.47bnCN¥3.39bnCN¥3.33bnCN¥3.26bnCN¥3.22bnCN¥3.11bnCN¥3.07bn

Financial ratios

Data as of 11 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin6.7%6.6%11.6%13.4%14.3%16.1%
Operating margin6.7%3.2%9.3%9.1%9.3%10.0%
Net margin5.5%1.3%7.0%6.9%7.2%6.8%
Return on equity10.7%3.0%13.8%13.7%12.6%13.0%
Return on assets3.8%1.0%5.6%6.3%5.9%5.8%
Free cash flow yield6.4%-1.2%-5.1%14.6%5.6%14.6%
Revenue growth-6.2%1.8%9.1%29.2%24.6%19.8%
Earnings growth286.7%-80.4%10.5%23.5%31.3%38.3%
Current ratio1.29x1.48x1.61x1.79x1.48x2.04x
Debt to equity0.01x1.08x0.90x0.89x0.88x1.01x
Equity ratio35.7%34.5%40.6%45.7%46.8%44.3%
Interest coverage4.85x1.90x7.66x8.28x8.32x4.94x
R&D as a share of sales2.5%1.8%1.4%2.0%1.9%2.1%
Buybacks as a share of market value9.4%5.7%-1.4%-0.5%6.6%-6.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.4%10.9%17.9%
Operating income-3.4%7.1%22.5%
Net income-5.7%6.3%18.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin6.6%9.5%10.9%11.8%
Operating margin4.0%5.9%6.4%6.1%
Net margin3.4%5.1%5.6%5.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings15.646.715.021.524.940.120.420.232.251.1
Price to sales0.90.61.01.51.82.81.21.01.72.2

Dividends and splits

Per share, in the currency the company pays

Paid for 15 years. Last went ex-dividend on 21 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.300.130.130.160.130.100.050.08
  • 7-for-5 split · 27 Jun 2018
  • 7-for-5 split · 16 Jun 2017
  • 6-for-5 split · 9 May 2016
  • 2-for-1 split · 24 Apr 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.